Tags

Type your tag names separated by a space and hit enter

Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study).
J Chemother. 2009 Apr; 21(2):170-80.JC

Abstract

This prospective, randomized, open, international, multicenter study of adults with complicated intra-abdominal infections (cIAI) compared the efficacy and safety of sequential intravenous (i.v.) to oral (p.o.) moxifloxacin 400 mg once daily, with that of i.v. ceftriaxone 2 g once daily, plus metronidazole 500 mg three times daily, followed by p.o. amoxicillin/clavulanate 625 mg three times daily. The primary efficacy variable was clinical cure at test of cure (TOC) (day 28-42 after study entry) in the per protocol (PP) population. Of 595 patients in the study, 511 patients were valid for PP analysis (246 moxifloxacin, 265 ceftriaxone/metronidazole). Sequential moxifloxacin was noninferior to the comparator regimen--clinical cure rates at TOC were 80.9% versus 82.3% (moxifloxacin versus ceftriaxone/metronidazole; 95% CI -8.9, 4.2%). The incidence of adverse events was comparable between the two treatment groups. Therefore, sequential moxifloxacin monotherapy is as effective and safe as combination therapy with i.v. ceftriaxone plus i.v. metronidazole followed by oral amoxicillin/clavulanate for the treatment of cIAI.

Authors+Show Affiliations

Department of Surgery, University Hospital, Magdeburg, Germany. guenter.weiss@klinikum-magdeburg.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase III
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19423470

Citation

Weiss, G, et al. "Moxifloxacin for the Treatment of Patients With Complicated Intra-abdominal Infections (the AIDA Study)." Journal of Chemotherapy (Florence, Italy), vol. 21, no. 2, 2009, pp. 170-80.
Weiss G, Reimnitz P, Hampel B, et al. Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study). J Chemother. 2009;21(2):170-80.
Weiss, G., Reimnitz, P., Hampel, B., Muehlhofer, E., & Lippert, H. (2009). Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study). Journal of Chemotherapy (Florence, Italy), 21(2), 170-80.
Weiss G, et al. Moxifloxacin for the Treatment of Patients With Complicated Intra-abdominal Infections (the AIDA Study). J Chemother. 2009;21(2):170-80. PubMed PMID: 19423470.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study). AU - Weiss,G, AU - Reimnitz,P, AU - Hampel,B, AU - Muehlhofer,E, AU - Lippert,H, AU - ,, PY - 2009/5/9/entrez PY - 2009/5/9/pubmed PY - 2009/7/16/medline SP - 170 EP - 80 JF - Journal of chemotherapy (Florence, Italy) JO - J Chemother VL - 21 IS - 2 N2 - This prospective, randomized, open, international, multicenter study of adults with complicated intra-abdominal infections (cIAI) compared the efficacy and safety of sequential intravenous (i.v.) to oral (p.o.) moxifloxacin 400 mg once daily, with that of i.v. ceftriaxone 2 g once daily, plus metronidazole 500 mg three times daily, followed by p.o. amoxicillin/clavulanate 625 mg three times daily. The primary efficacy variable was clinical cure at test of cure (TOC) (day 28-42 after study entry) in the per protocol (PP) population. Of 595 patients in the study, 511 patients were valid for PP analysis (246 moxifloxacin, 265 ceftriaxone/metronidazole). Sequential moxifloxacin was noninferior to the comparator regimen--clinical cure rates at TOC were 80.9% versus 82.3% (moxifloxacin versus ceftriaxone/metronidazole; 95% CI -8.9, 4.2%). The incidence of adverse events was comparable between the two treatment groups. Therefore, sequential moxifloxacin monotherapy is as effective and safe as combination therapy with i.v. ceftriaxone plus i.v. metronidazole followed by oral amoxicillin/clavulanate for the treatment of cIAI. SN - 1973-9478 UR - https://www.unboundmedicine.com/medline/citation/19423470/Moxifloxacin_for_the_treatment_of_patients_with_complicated_intra_abdominal_infections__the_AIDA_Study__ L2 - https://www.tandfonline.com/doi/full/10.1179/joc.2009.21.2.170 DB - PRIME DP - Unbound Medicine ER -